Posted BY: Kara | NwoReport

Big Pharma companies are reportedly gearing toward comprehensive treatment programs for autism spectrum disorder (ASD). This came on the heels of a recent report that the global ASD treatment market is projected to reach $11.42 billion by 2028.

The study conducted by market research firm 360 Research Reports may have “opened the eyes” of Big Pharma companies as the industry used to deny ASD’s existence and even avoid the slightest discussion of the treatment of autism. But now that the scale of the clinical population of people on the spectrum has been uncovered, these companies have started charting ways to boost their profits through treatment programs.

“For decades, the increase in autism was denied and any discussion of the treatment of autism was met with the same derisive forces that would malign and mischaracterize the parents and physicians trying to give these kids a better day,” said Dr. James Lyons-Weiler, a former University of Pittsburgh faculty member and author of “The Environmental and Genetic Causes of Autism.”

Trending: CDC bought access to Americans’ phone location data to monitor compliance with lockdowns, social distancing, and more, contracts show

“But now that Pharma has recognized the scale of the clinical population of people on the spectrum, it’s finally considered [acceptable] to admit the increase and to rush headlong into treatment programs.”

A recent study estimated a massive market expansion of up to 7.4 percent compound annual growth rate between now and 2030. It also assessed treatments and drugs used to diagnose and treat ASD, projected future profits by age group, geographic region and other factors, and analyzed the top Big Pharma industry players.

According to the report, the industry giants set to profit are Otsuka, which currently controls six percent of the market, followed by AstraZeneca, Pfizer, Eli Lilly, Johnson & Johnson, and Roche.

Full Story